Five takeaways from the company’s financial report released Nov. 2:
1. Revenue in the third quarter was $456.4 million, up 12 percent from the same period last year.
2. Net loss was $166.9 million, or $1.35 per share.
3. Screening revenue, which includes Cologuard tests, increased 31 percent to $280.4 million.
4. Precision oncology revenue was $145.4 million, a 59 percent increase compared to the same time last year. COVID-19 testing revenue was $30.6 million, down 70 percent for the same period.
5. Adjusted earnings before interest, taxes, depreciation and amortization was $16.3 million.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
